--- title: "The effect of menaquinone-7 supplementation on vascular…" description: "Menaquinone-7 supplementation did not reduce vascular calcification in patients with type 2 diabetes and cardiovascular disease, and may have slightly…" url: "https://magellanlongevity.com/study/d31387121.md" canonical: "https://magellanlongevity.com/study/d31387121.html" html: "https://magellanlongevity.com/study/d31387121.html" type: "study" study_key: "d31387121" journal: "Am J Clin Nutr" year: 2019 pmid: "31387121" doi: "10.1093/ajcn/nqz147" citations: 1 updated: 2026-09-02 author: "Gabriel Radu, DO" author_credentials: "Physiatrist (PM&R). NY medical license 275110. NPI 1376861765." publisher: "Magellan Longevity" content_format: "markdown" --- # The effect of menaquinone-7 supplementation on vascular calcification in patients with diabetes: a randomized controlled trial [Home](https://magellanlongevity.com/) › [Research map](https://magellanlongevity.com/longevity-research-map.html) › The effect of menaquinone-7 supplementation on vascular… **HTML version:** https://magellanlongevity.com/study/d31387121.html · **In the Magellan app:** https://magellanlongevity.com/#/study/d31387121 ## Citation | Field | Value | | --- | --- | | Journal | Am J Clin Nutr | | Year | 2019 | | PMID | [31387121](https://pubmed.ncbi.nlm.nih.gov/31387121/) | | DOI | [10.1093/ajcn/nqz147](https://doi.org/10.1093/ajcn/nqz147) | | Study key | d31387121 | ## Takeaway Menaquinone-7 supplementation did not reduce vascular calcification in patients with type 2 diabetes and cardiovascular disease, and may have slightly increased active calcification. ## The question Does menaquinone-7 supplementation decrease vascular calcification in patients with type 2 diabetes and cardiovascular disease? ## Hypothesis Menaquinone-7 supplementation, compared to placebo, will decrease vascular calcification in people with type 2 diabetes and known cardiovascular disease. ## Methods This was a double-blind, randomized, placebo-controlled trial. Participants with type 2 diabetes and cardiovascular disease were assigned to receive either 360 µg/d menaquinone-7 (MK-7) or placebo for 6 months. Femoral arterial calcification was measured at baseline and 6 months using 18F-NaF PET scans (target-to-background ratios, TBRs) for active calcification and conventional CT scans for calcification mass. Dephosphorylated-uncarboxylated matrix Gla protein (dp-ucMGP) concentrations were also measured. ## Results 35 patients were assigned to the MK-7 group (33 completed) and 33 to the placebo group (27 completed). After 6 months, TBR tended to increase in the MK-7 group compared with placebo (0.25; P = 0.06), though not significantly. Log-transformed CT calcification mass did not increase in the intervention group compared with placebo (0.50; P = 0.18). MK-7 supplementation significantly reduced dp-ucMGP compared with placebo (-205.6 pmol/L). No adverse events were reported. ## Conclusion Menaquinone-7 supplementation tended to increase active calcification as measured by 18F-NaF PET activity, but had no effect on conventional CT calcification. Further research is needed to interpret 18F-NaF PET activity. ## Limitations The study found a non-significant trend towards increased active calcification with MK-7, and the interpretation of 18F-NaF PET activity requires further investigation. ## Verbatim from the abstract > MK-7 supplementation significantly reduced dp-ucMGP compared with placebo ## Where this study is used on Magellan This paper is one of the citations behind the evidence grade on the pages below. Grades are assigned from the published research and are independent of affiliate commissions. | Compound or device | Evidence grade | Graded pages | | --- | --- | --- | | Vitamin K2 (MK-7) | Moderate evidence | [Vitamin K2 (MK-7)](https://magellanlongevity.com/p/138.md) | ## Reference 1. **The effect of menaquinone-7 supplementation on vascular calcification in patients with diabetes: a randomized controlled trial** Am J Clin Nutr 2019 · [PMID 31387121](https://pubmed.ncbi.nlm.nih.gov/31387121/) · [DOI 10.1093/ajcn/nqz147](https://doi.org/10.1093/ajcn/nqz147) > MK-7 supplementation significantly reduced dp-ucMGP compared with placebo ## Structured data ```json {"@context":"https://schema.org","@graph":[{"@type":"MedicalWebPage","@id":"https://magellanlongevity.com/study/d31387121.html#page","url":"https://magellanlongevity.com/study/d31387121.html","name":"The effect of menaquinone-7 supplementation on vascular calcification in patients with diabetes: a…","description":"Menaquinone-7 supplementation did not reduce vascular calcification in patients with type 2 diabetes and cardiovascular disease, and may have slightly…","inLanguage":"en","isPartOf":{"@type":"WebSite","name":"Magellan Longevity","url":"https://magellanlongevity.com/"},"author":{"@type":"Person","name":"Gabriel Radu, DO","jobTitle":"Physiatrist (PM&R)","identifier":[{"@type":"PropertyValue","name":"NPI","value":"1376861765"},{"@type":"PropertyValue","name":"NY medical license","value":"275110"}]},"publisher":{"@type":"Organization","name":"Magellan Longevity","url":"https://magellanlongevity.com/"},"encoding":{"@type":"MediaObject","encodingFormat":"text/markdown","contentUrl":"https://magellanlongevity.com/study/d31387121.md"},"dateModified":"2026-09-02"},{"@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://magellanlongevity.com/"},{"@type":"ListItem","position":2,"name":"Research map","item":"https://magellanlongevity.com/longevity-research-map.html"},{"@type":"ListItem","position":3,"name":"The effect of menaquinone-7 supplementation on vascular…","item":"https://magellanlongevity.com/study/d31387121.html"}]},{"@type":"ScholarlyArticle","@id":"https://magellanlongevity.com/study/d31387121.html#study","name":"The effect of menaquinone-7 supplementation on vascular calcification in patients with diabetes: a randomized controlled trial","headline":"The effect of menaquinone-7 supplementation on vascular calcification in patients with diabetes: a…","datePublished":"2019","isPartOf":{"@type":"Periodical","name":"Am J Clin Nutr"},"identifier":"PMID:31387121","url":"https://pubmed.ncbi.nlm.nih.gov/31387121/","sameAs":"https://doi.org/10.1093/ajcn/nqz147","abstract":"Menaquinone-7 supplementation did not reduce vascular calcification in patients with type 2 diabetes and cardiovascular disease, and may have slightly increased active calcification."}]} ``` ## Related on Magellan Longevity - [Vitamin K2 (MK-7)](https://magellanlongevity.com/p/138.md) — product graded on this and related evidence - [Evidence: matrix Gla-protein carboxylation](https://magellanlongevity.com/study/s138.md) - [Effect of vitamin K supplementation on arterial stiffness in vitamin K-deficient kidney…](https://magellanlongevity.com/study/d36695702.md) - [Longevity research map](https://magellanlongevity.com/longevity-research-map.html) - [Evidence-based longevity supplements](https://magellanlongevity.com/longevity-supplements.md) ## Scope and disclosures Educational information, not medical advice. Nothing here is intended to diagnose, treat, cure, or prevent any disease. Talk to your physician before starting any supplement or device, especially if you are pregnant, nursing, or taking medication. Editorial firewall: evidence grades are assigned from the published research and are independent of any affiliate commission. As an Amazon Associate, Magellan Longevity earns from qualifying purchases. Reviewed for accuracy by a board-certified physician (DO).